Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0341503 (
bacterial peritonitis
)
1,303
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Peritonitis- and catheter-related infections due to nontuberculous mycobacteria (NTM) including
Mycobacterium abscessus
have been reported among adults on peritoneal dialysis (PD). There is no recommended antimicrobial regimen for the treatment of
M. abscessus
peritonitis.
Clofazimine
has emerged as an important adjuvant antimicrobial treatment of
M. abscessus
lung infection. We report, to our knowledge, the first case of
M. abscessus
PD peritonitis in a child treated successfully using clofazimine as a novel adjuvant therapy to amikacin and clarithromycin. Her clinical features were similar to those of
bacterial peritonitis
, but she had persistence of symptoms and high inflammatory markers despite empirical therapy for peritonitis. Bacterial culture of PD effluent became positive for
M. abscessus
after 5 days. There was complete symptom resolution after 6 days of multidrug therapy. Due to ototoxicity, amikacin was discontinued after 6 weeks, while clarithromycin and clofazimine were continued for 9 months to ensure complete pathogen eradication before a planned renal transplant. A high index of suspicion in refractory or culture-negative cases is important for the diagnosis of NTM peritonitis. Multidrug therapy is recommended for
M. abscessus
infections.
Clofazimine
was chosen as a novel adjunct antimicrobial because of its pharmacokinetics, ease of administration, cost-effectiveness, and lack of serious adverse events.
...
PMID:Clofazimine in
Mycobacterium abscessus
peritonitis: A pediatric case report. 3214 78
